Amphion expects 2007 pretax profit to rise 50%

21 January 2008

UK-based Amphion Innovations says that its results for full-year 2007 are expected to show an increase in net asset value per share of 29% over the previous year to $0.44, broadly in line with market expectations. Profit before tax is expected to be $10.5 million, a 50% increase from the previous year, primarily reflecting the uplift in the value of its investments.

The firm says it currently has 10 partner companies developing proven technologies targeting substantial commercial marketplaces, in excess of $1.0 billion. Each partner aims to achieve a target exit value in excess of $100.0 million supported by Amphion management's record of delivering liquidity events. During 2007, Amphion noted that it successfully helped its partners raise over $21.0 million.

The firm expects to report its preliminary financial results in March 2008.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight